Aurora Cannabis (ACB) EBITDA Margin (2017 - 2026)
Aurora Cannabis (ACB) posted quarterly EBITDA Margin of 10.88% for Q1 2026, down 743.0% year-on-year from 1.69% in Q1 2025, and down 50.91% on a QoQ basis from 22.16% in Q4 2025.
Aurora Cannabis (ACB) EBITDA Margin (2017 - 2026) Analysis & Trends
Aurora Cannabis (ACB) has reported EBITDA Margin for 10 consecutive years, with 10.88% the latest figure, recorded in Q1 2026.
- Quarterly EBITDA Margin fell 743.0% year-over-year to 10.88% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.65% (up 303.0% YoY) and the FY2026 annual result came in at 14.55%, down 3422.0% from the prior year.
- EBITDA Margin eased to 10.88% in Q1 2026 per ACB's latest filing, from 22.16% in the prior quarter.
- Over the last five years, EBITDA Margin for ACB reached as high as 30.72% in Q4 2024 and fell as low as 1043.86% in Q2 2023.
- A 5-year average of 74.7% and a median of 0.27% in 2022 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin sank 92397 bps — and 2024, when it surged 104350 bps.
- Year by year, EBITDA Margin stood at 0.89% in 2022, then surged by 1127 bps to 10.93% in 2023, then surged by 181 bps to 30.72% in 2024, then declined by 28 bps to 22.16% in 2025, then slumped by 51 bps to 10.88% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 10.88%, 22.16%, and 4.34% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Aurora Cannabis | 1.11 Bn | 1.03 Bn | 21.72 Mn | 10.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.88% |
| Dec 31, 2025 | 22.16% |
| Sep 30, 2025 | 4.34% |
| Jun 30, 2025 | -1.54% |
| Mar 31, 2025 | 18.31% |
| Dec 31, 2024 | 30.72% |
| Sep 30, 2024 | -1.36% |
| Jun 30, 2024 | -0.36% |
| Mar 31, 2024 | 4.64% |
| Dec 31, 2023 | 10.93% |
| Sep 30, 2023 | -1.93% |
| Jun 30, 2023 | -1,043.86% |
| Dec 31, 2022 | 0.89% |
| Sep 30, 2022 | -109.31% |
| Jun 30, 2022 | -119.89% |
| Mar 31, 2022 | -19.86% |
| Dec 31, 2021 | -92.09% |
| Sep 30, 2021 | -20.14% |
| Jun 30, 2021 | 10.45% |
| Mar 31, 2021 | -259.16% |